Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer

详细信息    查看全文

• 作者：Sarah M. Crafton ; MD ; Ritu Salani ; MD ; MBA ; ^{ritu.salani@osumc.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：anti-angiogenesis ; cervical cancer ; immunotherapy ; PARP inhibitors ; targeted therapy
• 刊名：Clinical Therapeutics
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：38
• 期：3
• 页码：449-458
• 全文大小：196 K

文摘

The purpose of this study was to provide an overview of current and up and coming targeted therapies in cervical cancer with or without chemotherapy.

Methods

We reviewed the literature using search terms cervical cancer AND immunotherapy, immune therapy, vaccines, bevacizumab, anti-angiogenic therapy, and PARP inhibitors on PubMed. We included all review articles and prospective trials. We also reviewed ClinicalTrials.gov for trials in progress.

Findings

The addition of bevacizumab has improved the overall survival of women with advanced or recurrent cervical cancer when compared with cytotoxic therapy alone. This advancement has sparked an interest in other anti-angiogenic agents. Additionally, targeted therapies, including tyrosine kinase inhibitors, immunotherapy, and vaccine therapy, are also being evaluated. Another exciting area of study is the role of poly (ADP-ribose) polymerase inhibition in cervical cancer.

Implications

Though the results are promising, the data are preliminary and additional studies evaluating the proper combination of therapy, dosing, and schedules will help inform the ideal regimen.